US · BNTC
Benitec Biopharma Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Hayward, CA 94545
- Website
- benitec.com
Price · as of 2025-06-30
$11.95
Market cap 286.09M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $4,982.15 | $2,136.44 | $1.05 | $0.00 | $0.00 |
| 2015 | $1,844.11 | $772.88 | $9.22 | $0.00 | $616.50 |
| 2016 | $425.37 | $568.34 | $0.00 | $0.00 | $5,161.10 |
| 2017 | $519.61 | $3,511.19 | $0.00 | $0.00 | $0.00 |
| 2018 | $650.25 | $393.28 | $10.32 | $0.00 | $0.00 |
| 2019 | $165.24 | $6,918.94 | $11,337.23 | $100.40 | $21,322.40 |
| 2020 | $111.86 | $13,504.07 | $4.40 | $0.00 | $2,987.45 |
| 2021 | $67.15 | $98.36 | $4.95 | $0.00 | $403.34 |
| 2022 | $11.56 | $15.20 | $0.00 | $0.00 | $0.00 |
| 2023 | $3.08 | $2.65 | $0.00 | $0.00 | $0.00 |
| 2024 | $9.02 | $29.50 | |||
| 2025 | $13.91 |
AI valuation
Our deep-learning model estimates Benitec Biopharma Inc.'s (BNTC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $11.95
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BNTC | Benitec Biopharma Inc. | $11.95 | 286.09M | — | — | — | — | -13.28 | 5.18 | — | -9.76 | — | 5.18 | 0.00% | — | — | -52.46% | 2846.97% | -49.96% | 0.01 | — | 54.67 | 54.26 | 2.32 | -6082.00% | — | 2055.00% | -4.69% | -13.09 | 1609.13% | 0.00% | 0.00% | 9.20% | -9.74 | -17.23 | — | 128.14 |
| AUTL | Autolus Therapeutics plc | $1.71 | 455.11M | +3,826% | -33% | — | — | -2.32 | 1.20 | 50.68 | 0.10 | — | 1.24 | -1293.48% | -2385.63% | -2180.45% | -81.91% | 263.57% | -38.11% | 0.12 | -25.98 | 10.88 | 10.47 | 0.75 | -2750.00% | 49600.00% | 5398.00% | -47.01% | -3.40 | 263.21% | 0.00% | 0.00% | 0.00% | 0.09 | 0.09 | -2.23 | -1.19 |
| GALT | Galectin Therapeutics Inc… | $2.98 | 192.13M | — | — | — | — | -2.15 | -0.98 | — | -4.63 | -79.38 | -0.98 | 0.00% | — | — | 57.62% | 325.92% | -205.92% | -1.03 | -7.66 | 0.49 | 0.43 | -2.20 | 270.00% | — | 2670.00% | -41.38% | -1.18 | 320.80% | 0.09% | -0.20% | 0.09% | -4.53 | -4.60 | — | -40.88 |
| NGNE | Neurogene Inc. | $23.49 | 363.86M | — | -49% | — | — | -4.04 | 0.98 | 328.17 | -0.05 | -7.88 | 0.98 | -251.03% | -8930.27% | -8123.68% | -30.28% | -1064.50% | -26.92% | 0.04 | -6883.75 | 20.84 | 20.65 | 1.73 | 5124.00% | — | 3801.00% | -23.52% | -4.66 | -920.24% | 0.00% | 0.00% | 0.00% | -0.04 | -0.05 | 3.87 | 6.36 |
| OCGN | Ocugen, Inc. | $1.82 | 595.72M | +1,481% | -87% | — | +155% | -3.06 | 5.58 | 40.77 | -2.64 | — | 5.58 | 51.47% | -1350.36% | -1333.02% | -154.01% | -938.91% | -73.55% | 1.10 | — | 2.86 | 2.71 | 0.49 | -2308.00% | -3282.00% | -3723.00% | -27.54% | -1.95 | -780.64% | 0.00% | 0.00% | 0.00% | -2.54 | -3.06 | 34.35 | -5.46 |
| PRTC | PureTech Health plc | $16.77 | 405.3M | +112% | +57,154% | +51% | +506% | 17.42 | 1.17 | 100.26 | 3.72 | — | 1.17 | 26.04% | -2818.87% | 1108.33% | 6.32% | -117.31% | 4.29% | 0.05 | -13.56 | 9.33 | 9.19 | -6.91 | -18333.00% | 4498.00% | 2658.00% | -27.76% | -3.25 | -115.83% | 0.00% | 0.00% | 41.34% | -1.02 | -1.04 | 28.81 | 1.52 |
| QSI | Quantum-Si incorporated | $0.96 | 187.03M | +4,402% | -8% | — | — | -1.83 | 0.86 | 60.41 | 0.11 | -41.45 | 0.86 | 52.32% | -3550.56% | -3303.04% | -41.48% | -452.86% | -36.99% | 0.06 | — | 11.99 | 11.60 | 0.35 | 441.00% | 18262.00% | -698.00% | -50.01% | -4.83 | -385.30% | 0.00% | 0.00% | 0.00% | 0.11 | 0.13 | -3.90 | -0.42 |
| SLDB | Solid Biosciences Inc. | $6.21 | 483.82M | — | — | — | — | -1.77 | 1.61 | — | -0.79 | — | 1.61 | 0.00% | — | — | -94.57% | -623.56% | -70.53% | 0.18 | -381.55 | 5.20 | 4.92 | 0.46 | -3665.00% | — | 519.00% | -45.50% | -3.31 | -483.87% | 0.00% | 0.00% | 6.07% | -0.74 | -0.96 | — | -4.69 |
| XOMA | XOMA Royalty Corp. | $25.53 | 316.14M | +157% | -39% | — | — | -18.47 | 3.12 | 8.96 | -49.66 | — | 4.56 | 99.28% | -140.33% | -48.52% | -16.20% | -36.44% | -6.07% | 1.46 | -2.89 | 5.15 | 5.01 | -3.24 | -5916.00% | 49872.00% | -2425.00% | -5.39% | -0.56 | -17.69% | 2.14% | -39.60% | 2.15% | -6.74 | -19.56 | 9.45 | -6.65 |
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
- CEO
- Jerel A. Banks
- Employees
- 16
- Beta
- 0.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $11.95) − 1 = — (DCF, example).